Stock ELEV ELEVATION ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
2.35 USD -2.49% Intraday chart for Elevation Oncology, Inc. -14.86% +337.62%
05-31 Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target MT
05-14 Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Elevation Oncology, Inc. Announces Management Changes
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee
Elevation Oncology Says It Has Funds to Continue Operations Into H2 2025
Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021
Elevation Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Elevation Oncology Names Joseph Ferra CEO, Tammy Furlong Finance Chief
Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer
Oncology, Inc Appoints Joseph J. Ferra, Jr. as President of the Company and A Member of the Board, to Serve as A Class I Director
Top Midday Decliners
Looming CPI, Fed Rate Decision Drive Quiet Premarket Action for US Equity Futures
Top Premarket Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELEV Stock
  4. News Elevation Oncology, Inc.
  5. Other languages